Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
about
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropeniaVoriconazole versus amphotericin B in cancer patients with neutropeniaBitter pills and puffed trialsFlaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotationsRecommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Voriconazole: the newest triazole antifungal agentPharmacotherapy of Candida bloodstream infections: new treatment options, new era.Antifungal drug resistance.Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.Voriconazole: a new triazole antifungal agent.New and emerging antifungal agents: impact on respiratory infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.Pharmacoeconomics of voriconazole in the management of invasive fungal infections.Empiric antifungal therapy in patients with febrile neutropenia.Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital.Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.Use of antifungal agents in pediatric and adult high-risk areas.
P2860
Q24200304-B1D77470-9048-4F71-914E-B3E1D69420B9Q24244950-6E0E87F9-3168-4341-B631-A7A13BCBE6C5Q24815838-FAED0708-29A0-4CF8-90CC-983F3B604BA8Q25257632-2B260A88-2305-4E12-8042-A8CA02F19A43Q26824260-C2A44869-4A12-42D9-9C52-6487550DB5BAQ33946021-4D21759A-13C4-4462-93E4-11002A9DA361Q34768471-75847386-AB9D-4FAC-975D-B1231D8533DCQ35040008-8A06B501-2F03-453F-9EED-200EF22A5210Q35054434-BDF12DFD-25EF-4843-845D-84979E05E949Q35069136-04D18EA4-3CF3-4F71-A2DE-C25114059397Q35627629-1C8E358C-50F2-48EF-816F-8708A2E61CEDQ36491819-E1CBEAC1-D6F0-4C0A-9128-D7A85C6E2182Q36597431-7092672D-FF2C-4337-91FF-F8F62CE795B2Q37005474-D5F22891-3087-4E27-96D1-A1F81DA133D4Q37810091-E58BBC22-A847-443D-A046-2F5CEAA2D2D8Q37820674-1A74EDA5-D395-4666-8423-52C2A8DE2779Q37859365-0D165340-1C92-43C7-97B6-52D99D72A3D9Q38070844-6F5C9051-1CFB-41EC-9F97-5B7CE4C0399CQ38115356-6EED0EB4-BC57-44F8-B3E7-7198BFF165B6Q40446187-1E281BC8-04CD-4674-91D2-AF43533FB381Q44506237-68E79FE1-D1E1-488A-8699-B1F08A5871C8
P2860
Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Voriconazole versus liposomal ...... tropenia and persistent fever.
@en
Voriconazole versus liposomal ...... tropenia and persistent fever.
@nl
type
label
Voriconazole versus liposomal ...... tropenia and persistent fever.
@en
Voriconazole versus liposomal ...... tropenia and persistent fever.
@nl
prefLabel
Voriconazole versus liposomal ...... tropenia and persistent fever.
@en
Voriconazole versus liposomal ...... tropenia and persistent fever.
@nl
P2093
P1476
Voriconazole versus liposomal ...... tropenia and persistent fever.
@en
P2093
Cheryl A Dixon
John H Powers
Mark J Goldberger
P304
P356
10.1056/NEJM200201243460414
P407
P577
2002-01-01T00:00:00Z